Trials / Completed
CompletedNCT04925141
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Efficacy and Safety of Dasatinib in the First-line Treatment of Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 62 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this multicenter,open, prospective and single arm study is to evaluate the efficacy and safety of domestic dasatinib in the first-line treatment of newly diagnosed CML-CP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dasatinib Tablets | Tyrosine Kinase Inhibitor (TKI) |
Timeline
- Start date
- 2016-05-10
- Primary completion
- 2018-10-22
- Completion
- 2019-12-06
- First posted
- 2021-06-14
- Last updated
- 2021-06-14
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04925141. Inclusion in this directory is not an endorsement.